High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab Sep 11, 2023
Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment One of 40 patients changed treatment but all remained on brentuximab regardless of scan results Sep 09, 2023
Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies Increased risk for non-melanoma skin cancer, MDS, AML versus the general population Sep 09, 2023
Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes Molecular or cytogenetic response at 3 months correlated with better survival Sep 08, 2023
Intensive Pretransplant Consolidation in Older AML Fails to Improve Results Newer therapies and strategies might show more promise for boosting survival Sep 07, 2023
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival Sep 07, 2023
Cancer Patients More Likely to Die During COVID Pandemic Omicron wave was especially deadly, and those with blood cancers at increased risk Sep 01, 2023
Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancer News, features, and commentary about cancer-related issues Sep 01, 2023
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma Mezigdomide led to 41% response rate in heavily pretreated patients Aug 30, 2023
U.S. Unveils First 10 Drugs for Medicare Price Negotiations Treatments for heart failure, Crohn's disease, and diabetes make the list Aug 29, 2023
Adenovirus May Trigger Thrombocytopenia, Thrombosis, Case Studies Suggest First reports of an anti-PF4 disorder associated with an adenovirus infection Aug 09, 2023
Adcetris Plus Chemo Effective in HIV-Related Hodgkin Lymphoma Researchers call study "practice changing," although outside experts urge caution Aug 04, 2023
Anti-PD-1 Alone Produces Durable Responses in Relapsed/Refractory PMBCL More than 80% of responding patients remained in response at 4 years Jul 24, 2023
New Recommendations Address Global Inequality in Sickle Cell Disease Care Commission lays out strategies for progress by 2025 and beyond Jul 13, 2023
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
FDA Gives Nod to Gene Therapy for Hemophilia A First gene therapy approved for severe hemophilia A Jun 29, 2023
TXA Holds Its Own for Heavy Menstrual Bleeding in von Willebrand Disease In phase III study, recombinant VWF not superior to cheaper alternative for type 1 and 2 cases Jun 29, 2023
No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL Study suggests "watch and wait" should remain standard of care Jun 28, 2023
New Bispecific Antibody Approved for Tough-to-Treat Lymphoma Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate Jun 16, 2023
Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis Patients with depression alone had the worst overall survival Jun 13, 2023
CRISPR Therapy Exceeds Targets in Thalassemia, Sickle Cell Disease Results "indicate that exa-cel can provide a one-time functional cure," says researcher Jun 13, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma The CAR T-cell therapy led to significantly longer overall survival Jun 05, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS Results suggest a "paradigm shift" in the treatment of anemia for these patients May 25, 2023
Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
Mysterious White Blood Cell Disorder Not Just 'AIDS Without HIV' Idiopathic CD4 lymphocytopenia not so heterogenous after all May 03, 2023
Sodium Thiosulphate Not Much Help for Calciphylaxis in CKD Though used off-label for years, treatment isn't very beneficial Apr 26, 2023
Blinatumomab Plus Chemo Effective in Aggressive Infant ALL Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS Apr 20, 2023
Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
Oral Drug Improves Sunlight Tolerance in Genetic Photosensitivity Disorders Dersimelagon significantly extended time to sun-related prodromal symptoms Apr 12, 2023
Blood Donor's Sex Makes No Difference for Survival Only difference seen was higher incidence of MRSA infection in recipients of female donor blood Apr 12, 2023
SYK Inhibitor Promising in Early Trial of Primary ITP Sovleplenib demonstrated "consistent response" as second-line treatment Apr 11, 2023
